23948sdkhjf
Logga in eller skapa för att spara artiklar
Få tillgång till allt innehåll på Life Science Sweden
Ingen bindningstid eller kortinformation krävs
Gäller endast personlig prenumeration.
Kontakta oss för en företagslösning.

Novo Nordisk establishes new factory in Denmark

Novo Nordisk establishes a new production facility in Odense, Denmark, an investment of 8.5 billion Danish kroner.

The new factory, including a warehouse, will cover 40,000 square meters. Construction has already begun, and the facility is expected to be completed in 2027, according to a press release.

– We are proud to build on our legacy in Denmark and look forward to embarking on this journey in Odense, a well-connected city with a dynamic community and skilled workforce, says Henrik Wulff, Executive Vice President for Product Supply, Quality & IT at Novo Nordisk.

The investment is expected to create approximately 400 new jobs.

In addition, Novo Nordisk has received approval for its acquisition of the contract manufacturer Catalent for $11.7 billion. The acquisition means Novo Nordisk will take over Catalent's three pharmaceutical production facilities located in Italy, Belgium, and the USA.

News in English Se tema
BREAKING
{{ article.headline }}
0.106